Literature DB >> 11437986

Phase III of the migrating motor complex: associated with endogenous xenin plasma peaks and induced by exogenous xenin.

G E Feurle1, A Pfeiffer, T Schmidt, E Dominguez-Munoz, P Malfertheiner, G Hamscher.   

Abstract

Xenin, a recently discovered peptide produced by specific endocrine cells of the duodenal mucosa, has shown exocrine, endocrine and motility effects in the gastroenteropancreatic system in animal experiments. The aim of the present investigation was to study the role of xenin in the regulation of duodenojejunal motility of humans. Twenty-nine healthy volunteers from the hospital staff gave informed consent to participate in this investigation. In 20 volunteers, we determined plasma concentrations of immunoreactive xenin at 15 min intervals over a mean time period of 8 h fasting and recorded the interdigestive motor activity of the duodenojejunum. In a double-blind randomized crossover study on other nine subjects, synthetic xenin in a dose of 4 pmol kg-1 min-1 or placebo was infused for 10 min intravenously in the interdigestive period and postprandially after a liquid meal. Duodenojejunal motility was recorded simultaneously. Predefined interdigestive xenin plasma peaks were found to be significantly associated with the phases III of the migrating motor complex. In the interdigestive period, xenin induced a premature phase III activity in each volunteer; this was followed by a second phase III in five out of nine subjects. In the postprandial state, xenin significantly increased contraction frequency and the percentage of aborally propagated contractions. These findings suggest a role of the peptide hormone xenin in modulating interdigestive and postprandial duodenojejunal motility in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437986     DOI: 10.1046/j.1365-2982.2001.00263.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

1.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

Review 2.  The migrating motor complex: control mechanisms and its role in health and disease.

Authors:  Eveline Deloose; Pieter Janssen; Inge Depoortere; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-27       Impact factor: 46.802

3.  The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.

Authors:  Sara Chowdhury; Songyan Wang; Bruce W Patterson; Dominic N Reeds; Burton M Wice
Journal:  Regul Pept       Date:  2013-10-29

4.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

5.  Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.

Authors:  Burton M Wice; Dominic N Reeds; Hung D Tran; Dan L Crimmins; Bruce W Patterson; Judit Dunai; Michael J Wallendorf; Jack H Ladenson; Dennis T Villareal; Kenneth S Polonsky
Journal:  Diabetes       Date:  2012-04-20       Impact factor: 9.461

Review 6.  Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion.

Authors:  Van B Lu; Fiona M Gribble; Frank Reimann
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.